Published in Medical Letter on the CDC and FDA, November 6th, 2005
This antibody is used in tests to identify breast cancer patients eligible for treatment with the cancer drug Herceptin (Trastuzumab). InSite HER-2/neu (CB11) is available as a ready-to-use reagent, in manual and automated formats, and is allowed for use with BioGenex Super Sensitive Detection Systems. The automated format is approved for use on the BioGenex i6000 Automated Staining System and the Optimax Plus Consolidated Staining System.
Both manual and automated versions of InSite...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.